JOIN US!
Adicet Bio, Inc. is a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. Adicet is advancing a pipeline of “off-the-shelf” gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. For more information, please visit our website at https://www.adicetbio.com.
Process Development Engineer 2/3
Responsibilities:
- Lead and execute experiments to support process development, process scale-up, and technology transfer of ɣδ CAR T- cell products
- Execute cell culture-based experiments utilizing novel technologies to improve and scaling-up processes such as novel isolation methods, new bioreactors, and new reagents
- Create improvements to the platform process for activation, transduction, and expansion unit operations
- Perform multi-color flow cytometry acquisition and analysis
- Tracking and ordering requisite consumables for PD and MS&T teams
- Accurately compile data in electronic notebook entries and aggregate data files
Qualifications:
- BS/MS in Biochemical Engineering, Chemical Engineering, Science or Biotechnology.
- BS with 3-5 years or MS with 2+ years’ experience in industry setting
- A strong background in cell therapy or CAR T products required
- Experience in aseptic technique, cell culture, and retroviral or lentiviral transductions
- Experience with scale-up cell processing equipment such as closed system bioreactors, LOVO, Sefia, CliniMACS
- Familiar with flow cytometry for T cells and FlowJo
- Experience with Microsoft Office suite, JMP, Prism, Benchling (or other electronic lab notebook software)
- Experience with GMP processing and/or tech transfer related activities a plus
- Experience with analysis and reporting results, and interpretation of data.
- Possesses good verbal and written communication skills
- Ability to operate in a fast paced, dynamic industrial environment
Pay Range
$94,000—$130,000 USD
Adicet fosters a collaborative, high-performing environment by prioritizing in-person engagement. To enhance teamwork and communication, employees are required to be onsite at least three days per week (Tuesday–Thursday mandatory), with some roles requiring full-time onsite presence.
At Adicet, our people are our greatest focus. We believe that attracting and retaining the best and brightest is the key to achieving our mission to deliver best-in-class gamma delta T cell therapies for patients fighting autoimmune diseases and cancer.
We offer a competitive compensation package including base salary, annual cash bonus, long-term incentives (equity), Employee Stock Purchase Plan (ESPP) and a 401(k) with ROTH and a 4.5% Company match.
To ensure the wellness of our employees and their loved ones, we offer comprehensive health plans (medical, dental, vision, etc.), Flexible Health and Commuter Spending Accounts (FSA) and a company matched Health Savings Account (HSA). We also offer a life, AD&D, short and long-term disability insurance, and legal, pet, and various other voluntary insurance programs.
We also believe our greatest ideas come when we are refreshed and focused, and we offer generous paid time-off including 13 company holidays, paid end-of-year winter break, vacation, sick time, and paid parental leave.
Adicet is located in a state-of-the-art facility and works to create an incredible office experience with an onsite gym and various other fitness options, onsite parking with electric vehicle charging stations and free shuttle (Caltrain), company-subsidized lunches (delivered onsite daily) and fully stocked breakrooms.
Adicet is committed to creating a diverse environment and is proud to be an equal opportunity employer. All qualified applicants will receive consideration for employment without regard to race, color, religion, gender, gender identity or expression, sexual orientation, national origin, genetics, disability, age, or veteran status.
Top Skills
What We Do
At Adicet (Nasdaq: ACET), we are defined by our mission to deliver best-in-class gamma-delta T cell therapies for patients fighting cancer. Every one of our team members, whether in the lab, manufacturing, or general business role, comes to work every day with the patient in mind.
As pioneers in the cell therapy space, we are honored and humbled by the opportunity to put our talents to bear in developing transformative therapies to defeat cancer. We believe that the best way to do this is through discovering and developing allogeneic gamma-delta T cell therapies, a novel type of cell therapy.
Adicet has chosen the gamma-delta T cell because it has multiple ways to target and kill cancer cells, which may provide a better chance of achieving complete and durable responses to therapy. Additionally, instead of using cells from the already sick cancer patient, Adicet uses cells from unrelated donors (allogeneic) because they are reliable and readily available allowing us to rapidly and cost-effectively scale production of these medicines and make them available when needed (“off-the-shelf”).
Specifically, as a clinical stage biotechnology company we are advancing a pipeline of “off-the-shelf” gamma delta T cells, engineered with chimeric antigen receptors (CAR) and T cell receptor-like antibodies (TCRL) to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and improve persistence for durable activity in patients.
